The Abbott MitraClip™ G4 is a next-generation transcatheter edge-to-edge repair (TEER) system designed for the minimally invasive treatment of mitral regurgitation (MR) in patients with complex mitral valve disease. Engineered to deliver tailored therapy, optimized procedural control, and durable clinical outcomes, the MitraClip G4 platform features four clip configurations — NT, NTW, XT, and XTW — enabling physicians to adapt treatment based on individual mitral valve anatomy and regurgitation characteristics. The system incorporates advanced Controlled Gripper Actuation (CGA) technology for independent leaflet grasping, enhanced coaptation area, improved leaflet retention, and precise procedural control during transcatheter mitral valve repair procedures. Clinical studies from the EXPAND G4 trial demonstrated high procedural success, significant and durable MR reduction, improved quality of life, and excellent long-term safety outcomes, including MR ≤1+ in a large proportion of patients at one year follow-up. Designed for precision, stability, and workflow efficiency, the MitraClip G4 delivery system supports simplified procedural steps, optimized left atrial access, and stable device orientation for predictable and reproducible clinical performance in structural heart interventions.

The Pulsta™ Transcatheter Pulmonary Valve (TPV) System is an advanced self-expandable pulmonary valve replacement solution developed for the minimally invasive treatment of right ventricular outflow tract (RVOT) dysfunction and severe pulmonary regurgitation. Designed with a knitted-wire self-expandable stent structure, the Pulsta™ valve eliminates the need for pre-stenting and is suitable for native RVOT anatomies. The system features multi-step tissue engineering technology with alpha-galactosidase treatment to enhance valve durability and long-term performance. Available in multiple valve sizes up to 32 mm, the Pulsta™ TPV System provides flexible treatment options for a broad range of patient anatomies. Its low-profile 18–20 Fr delivery system, optimized landing zone deployment, and simplified loading procedure support precise implantation and procedural efficiency in transcatheter pulmonary valve interventions. Clinical studies have demonstrated favorable early and mid-term outcomes, making the Pulsta™ system an innovative solution for structural heart and congenital cardiac therapies.

The Abbott TriClip™ G4 is an advanced transcatheter edge-to-edge repair (TEER) system specifically developed for the minimally invasive treatment of severe tricuspid regurgitation (TR). Designed to provide exceptional safety, precise leaflet control, and durable clinical outcomes, the TriClip™ G4 platform enables physicians to restore tricuspid valve function in patients who are not suitable candidates for open-heart surgery. The system features anatomically optimized delivery curves, multi-axis steering capability, independent leaflet grasping technology, and multiple clip size options — NT, NTW, XT, and XTW — allowing tailored treatment across a wide range of tricuspid valve anatomies. Engineered for stable navigation and controlled implantation, the TriClip™ system enhances procedural efficiency while minimizing leaflet trauma and procedural complications. Clinical studies including the TRILUMINATE™ trial demonstrated significant and sustained tricuspid regurgitation reduction, high implant success rates, improved NYHA functional class, and substantial quality-of-life improvements in patients undergoing TriClip™ TEER therapy. With proven safety, durable valve repair performance, and minimally invasive treatment capability, the TriClip™ G4 system represents a next-generation solution for structural heart and tricuspid valve interventions.